CAS 56592-32-6

Efrotomycin

Description:

Efrotomycin, with the CAS number 56592-32-6, is an antibiotic belonging to the class of macrolides. It is primarily used for its antibacterial properties, particularly against Gram-positive bacteria. The substance exhibits a mechanism of action that involves inhibiting bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby preventing the growth and reproduction of bacteria. Efrotomycin is characterized by its relatively broad spectrum of activity, making it effective in treating various infections. It is typically administered via injection and is known for its pharmacokinetic properties, which include good tissue penetration and a moderate half-life. The compound is also subject to metabolic processes in the liver, and its excretion primarily occurs through the bile. As with many antibiotics, the potential for resistance development is a concern, necessitating careful use in clinical settings. Overall, efrotomycin represents a valuable option in the arsenal of antimicrobial agents, particularly in the treatment of specific bacterial infections.

Formula: C₅₉H₈₈N₂O₂₀

InChI: InChI=1S/C59H88N2O20/c1-15-17-19-27-39-58(8,9)53(80-56-45(67)50(74-13)49(35(7)76-56)79-57-51(75-14)44(66)48(73-12)34(6)77-57)52(68)59(71,81-39)36(16-2)54(69)60-29-23-22-25-32(4)46(72-11)33(5)47-43(65)42(64)38(78-47)26-21-18-20-24-31(3)41(63)40-37(62)28-30-61(10)55(40)70/h15,17-28,30,33-36,38-39,42-53,56-57,62,64-68,71H,16,29H2,1-14H3,(H,60,69)/b17-15-,20-18+,23-22+,26-21+,27-19+,31-24+,32-25+/t33-,34+,35-,36-,38-,39+,42+,43+,44-,45-,46-,47+,48+,49-,50+,51-,52-,53+,56+,57+,59-/m1/s1

InChI key: InChIKey=ASOJLQIBBYOFDE-SBHXXGSWSA-N

SMILES: [C@H](C(NC/C=C/C=C(/[C@H]([C@@H](C)[C@@]1(O[C@H](/C=C/C=C/C=C(/C(=O)C=2C(=O)N(C)C=CC2O)\C)[C@H](O)[C@@H]1O)[H])OC)\C)=O)(CC)[C@]3(O)[C@H](O)[C@H](O[C@H]4[C@H](O)[C@H](OC)[C@H](O[C@H]5[C@H](OC)[C@H](O)[C@@H](OC)[C@H](C)O5)[C@@H](C)O4)C(C)(C)[C@H](/C=C/C=C\C)O3

Synonyms:

• (alphaS,2R,3R,4R,6S)-4-((6-Deoxy-4-O-(6-deoxy-2,4-di-O-methyl-alpha-L-mannopyranosyl)-3-O-methyl-beta-D-allopyranosyl)oxy)-N-((2E,4E,6S,7R)-7-((2S,3S,4R,5R)-5-((1E,3E,5E)-6-(1,2-dihydro-4-hydroxy-1-methyl-2-oxonicotinoyl)-1,3,5-heptatrienyl)tetrahydro-3,4-dihydroxy-2-furyl)-6-methoxy-5-methyl-2,4-octadienyl)-alpha-ethyltetrahydro-2,3-dihydroxy-5,5-dimethyl-6-((1E,3Z)-1,3-pentadienyl)-2H-pyran-2-acetamide
• (αS,2R,3R,4R,6S)-4-[[6-Deoxy-4-O-(6-deoxy-2,4-di-O-methyl-α-<span class="text-smallcaps">L</smallcap>-mannopyranosyl)-3-O-methyl-β-<smallcap>D</span>-allopyranosyl]oxy]-N-[(2E,4E,6S,7R)-7-[(2S,3S,4R,5R)-5-[(1E,3E,5E)-7-(1,2-dihydro-4-hydroxy-1-methyl-2-oxo-3-pyridinyl)-6-methyl-7-oxo-1,3,5-heptatrien-1-yl]tetrahydro-3,4-dihydroxy-2-furanyl]-6-methoxy-5-methyl-2,4-octadien-1-yl]-α-ethyltetrahydro-2,3-dihydroxy-5,5-dimethyl-6-(1E,3Z)-1,3-pentadien-1-yl-2H-pyran-2-acetamide
• 2H-Pyran-2-acetamide, 4-[[6-deoxy-4-O-(6-deoxy-2,4-di-O-methyl-α-<span class="text-smallcaps">L</smallcap>-mannopyranosyl)-3-O-methyl-β-<smallcap>D</span>-allopyranosyl]oxy]-N-[(2E,4E,6S,7R)-7-[(2S,3S,4R,5R)-5-[(1E,3E,5E)-7-(1,2-dihydro-4-hydroxy-1-methyl-2-oxo-3-pyridinyl)-6-methyl-7-oxo-1,3,5-heptatrien-1-yl]tetrahydro-3,4-dihydroxy-2-furanyl]-6-methoxy-5-methyl-2,4-octadien-1-yl]-α-ethyltetrahydro-2,3-dihydroxy-5,5-dimethyl-6-(1E,3Z)-1,3-pentadien-1-yl-, (αS,2R,3R,4R,6S)-
• 2H-Pyran-2-acetamide, 4-[[6-deoxy-4-O-(6-deoxy-2,4-di-O-methyl-α-<span class="text-smallcaps">L</smallcap>-mannopyranosyl)-3-O-methyl-β-<smallcap>D</span>-allopyranosyl]oxy]-N-[(2E,4E,6S,7R)-7-[(2S,3S,4R,5R)-5-[(1E,3E,5E)-7-(1,2-dihydro-4-hydroxy-1-methyl-2-oxo-3-pyridinyl)-6-methyl-7-oxo-1,3,5-heptatrienyl]tetrahydro-3,4-dihydroxy-2-furanyl]-6-methoxy-5-methyl-2,4-octadienyl]-α-ethyltetrahydro-2,3-dihydroxy-5,5-dimethyl-6-[(1E,3Z)-1,3-pentadienyl]-, (αS,2R,3R,4R,6S)-
• Antibiotic FR 02A
• Brn 5230192
• Efrotomicina
• Efrotomicina [Spanish]
• Efrotomycin A₁
• Efrotomycin [USAN:INN:BAN]
• Efrotomycine
• Efrotomycine [French]
• Fr 02A
• Mk-621
• Mocimycin, 31-O-(6-deoxy-4-O-(6-deoxy-2,4-di-O-methyl-alpha-L-mannopyranosyl)-3-O-methyl-beta-D-allopyranosyl)-1-methyl-
• Mocimycin, 31-O-[6-deoxy-4-O-(6-deoxy-2,4-di-O-methyl-α-<span class="text-smallcaps">L</smallcap>-mannopyranosyl)-3-O-methyl-β-<smallcap>D</span>-allopyranosyl]-1-methyl-
• Producil
• Unii-5Bpj82Q45X
• (αS,2R,3R,4R,6S)-4-[[6-Deoxy-4-O-(6-deoxy-2,4-di-O-methyl-α-L-mannopyranosyl)-3-O-methyl-β-D-allopyranosyl]oxy]-N-[(2E,4E,6S,7R)-7-[(2S,3S,4R,5R)-5-[(1E,3E,5E)-7-(1,2-dihydro-4-hydroxy-1-methyl-2-oxo-3-pyridinyl)-6-methyl-7-oxo-1,3,5-heptatrien-1-yl]tetrahydro-3,4-dihydroxy-2-furanyl]-6-methoxy-5-methyl-2,4-octadien-1-yl]-α-ethyltetrahydro-2,3-dihydroxy-5,5-dimethyl-6-(1E,3Z)-1,3-pentadien-1-yl-2H-pyran-2-acetamide
• 2H-Pyran-2-acetamide, 4-[[6-deoxy-4-O-(6-deoxy-2,4-di-O-methyl-α-L-mannopyranosyl)-3-O-methyl-β-D-allopyranosyl]oxy]-N-[(2E,4E,6S,7R)-7-[(2S,3S,4R,5R)-5-[(1E,3E,5E)-7-(1,2-dihydro-4-hydroxy-1-methyl-2-oxo-3-pyridinyl)-6-methyl-7-oxo-1,3,5-heptatrienyl]tetrahydro-3,4-dihydroxy-2-furanyl]-6-methoxy-5-methyl-2,4-octadienyl]-α-ethyltetrahydro-2,3-dihydroxy-5,5-dimethyl-6-[(1E,3Z)-1,3-pentadienyl]-, (αS,2R,3R,4R,6S)-
• 2H-Pyran-2-acetamide, 4-[[6-deoxy-4-O-(6-deoxy-2,4-di-O-methyl-α-L-mannopyranosyl)-3-O-methyl-β-D-allopyranosyl]oxy]-N-[(2E,4E,6S,7R)-7-[(2S,3S,4R,5R)-5-[(1E,3E,5E)-7-(1,2-dihydro-4-hydroxy-1-methyl-2-oxo-3-pyridinyl)-6-methyl-7-oxo-1,3,5-heptatrien-1-yl]tetrahydro-3,4-dihydroxy-2-furanyl]-6-methoxy-5-methyl-2,4-octadien-1-yl]-α-ethyltetrahydro-2,3-dihydroxy-5,5-dimethyl-6-(1E,3Z)-1,3-pentadien-1-yl-, (αS,2R,3R,4R,6S)-

Efrotomycin

CAS: 56592-32-6

Efrotomycin: an oral antibiotic from Streptomyces Lactamdurans; minimal effect on Salmonella in pigs.

Formula: C₅₉H₈₈N₂O₂₀

Color and Shape: Solid

Molecular weight: 1145.33

Ref: TM-T73910